Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Completed Phase 2 Trials for Saracatinib (DB11805)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00513435Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment